Similar articles for PMID: 29025987

Year	Number of Results
2003	2
2004	4
2009	1
2010	4
2011	3
2012	4
2013	3
2014	2
2015	3
2016	8
2017	10
2018	19
2019	19
2020	37
2021	38
2022	91
2023	35
2024	0

1

Preclinical Development of CD38-Targeted [⁸⁹Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.

Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, Shen D, DiPersio J, Akers W, Dehdashti F, Achilefu S, Vij R, Shokeen M. Ghai A, et al. J Nucl Med. 2018 Feb;59(2):216-222. doi: 10.2967/jnumed.117.196063. Epub 2017 Oct 12. J Nucl Med. 2018. PMID: 29025987 Free PMC article.

2

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.

Ulaner GA, Sobol NB, O'Donoghue JA, Kirov AS, Riedl CC, Min R, Smith E, Carter LM, Lyashchenko SK, Lewis JS, Landgren CO. Ulaner GA, et al. Radiology. 2020 Jun;295(3):606-615. doi: 10.1148/radiol.2020192621. Epub 2020 Apr 7. Radiology. 2020. PMID: 32255416 Free PMC article. Clinical Trial.

3

Development of [⁸⁹Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.

Ghai A, Zheleznyak A, Mixdorf M, O'Neal J, Ritchey J, Rettig M, DiPersio J, Shokeen M, Achilefu S. Ghai A, et al. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1302-1311. doi: 10.1007/s00259-020-05097-y. Epub 2020 Nov 11. Eur J Nucl Med Mol Imaging. 2021. PMID: 33179150 Free PMC article.

4

ImmunoPET imaging of CD38 in murine lymphoma models using ⁸⁹Zr-labeled daratumumab.

Kang L, Jiang D, England CG, Barnhart TE, Yu B, Rosenkrans ZT, Wang R, Engle JW, Xu X, Huang P, Cai W. Kang L, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1372-1381. doi: 10.1007/s00259-018-3941-3. Epub 2018 Feb 15. Eur J Nucl Med Mol Imaging. 2018. PMID: 29450576 Free PMC article.

5

CD38 as a PET Imaging Target in Lung Cancer.

Ehlerding EB, England CG, Jiang D, Graves SA, Kang L, Lacognata S, Barnhart TE, Cai W. Ehlerding EB, et al. Mol Pharm. 2017 Jul 3;14(7):2400-2406. doi: 10.1021/acs.molpharmaceut.7b00298. Epub 2017 Jun 8. Mol Pharm. 2017. PMID: 28573863 Free PMC article.

6

Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.

Cho N, Ko S, Shokeen M. Cho N, et al. Mol Imaging Biol. 2021 Apr;23(2):186-195. doi: 10.1007/s11307-020-01542-4. Epub 2020 Sep 22. Mol Imaging Biol. 2021. PMID: 32964391 Free PMC article.

7

Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.

Bhattacharyya S, Kurdziel K, Wei L, Riffle L, Kaur G, Hill GC, Jacobs PM, Tatum JL, Doroshow JH, Kalen JD. Bhattacharyya S, et al. Nucl Med Biol. 2013 May;40(4):451-7. doi: 10.1016/j.nucmedbio.2013.01.007. Epub 2013 Feb 27. Nucl Med Biol. 2013. PMID: 23454247 Free PMC article.

8

Light-Induced Radiosynthesis of ⁸⁹Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor.

Klingler S, Fay R, Holland JP. Klingler S, et al. J Nucl Med. 2020 Jul;61(7):1072-1078. doi: 10.2967/jnumed.119.237180. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924725 Free PMC article.

9

Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.

Rylova SN, Del Pozzo L, Klingeberg C, Tönnesmann R, Illert AL, Meyer PT, Maecke HR, Holland JP. Rylova SN, et al. J Nucl Med. 2016 Jan;57(1):96-102. doi: 10.2967/jnumed.115.162735. Epub 2015 Oct 29. J Nucl Med. 2016. PMID: 26514172 Free article.

10

²¹²Pb α-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study.

Quelven I, Monteil J, Sage M, Saidi A, Mounier J, Bayout A, Garrier J, Cogne M, Durand-Panteix S. Quelven I, et al. J Nucl Med. 2020 Jul;61(7):1058-1065. doi: 10.2967/jnumed.119.239491. Epub 2019 Dec 20. J Nucl Med. 2020. PMID: 31862796 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

234 results

Results by year